Literature DB >> 30885970

High-dose influenza vaccination.

Daniel Dalcin1, Jeffrey C Kwong2.   

Abstract

Mesh:

Substances:

Year:  2019        PMID: 30885970      PMCID: PMC6422785          DOI: 10.1503/cmaj.181477

Source DB:  PubMed          Journal:  CMAJ        ISSN: 0820-3946            Impact factor:   8.262


× No keyword cloud information.
  4 in total

1.  Randomized, double-blind controlled phase 3 trial comparing the immunogenicity of high-dose and standard-dose influenza vaccine in adults 65 years of age and older.

Authors:  Ann R Falsey; John J Treanor; Nadia Tornieporth; Jose Capellan; Geoffrey J Gorse
Journal:  J Infect Dis       Date:  2009-07-15       Impact factor: 5.226

2.  Comparative Effectiveness of High-Dose Versus Standard-Dose Influenza Vaccines Among US Medicare Beneficiaries in Preventing Postinfluenza Deaths During 2012-2013 and 2013-2014.

Authors:  David K Shay; Yoganand Chillarige; Jeffrey Kelman; Richard A Forshee; Ivo M Foppa; Michael Wernecke; Yun Lu; Jill M Ferdinands; Arjun Iyengar; Alicia M Fry; Chris Worrall; Hector S Izurieta
Journal:  J Infect Dis       Date:  2017-02-15       Impact factor: 5.226

3.  Efficacy of high-dose versus standard-dose influenza vaccine in older adults.

Authors:  Carlos A DiazGranados; Andrew J Dunning; Murray Kimmel; Daniel Kirby; John Treanor; Avi Collins; Richard Pollak; Janet Christoff; John Earl; Victoria Landolfi; Earl Martin; Sanjay Gurunathan; Richard Nathan; David P Greenberg; Nadia G Tornieporth; Michael D Decker; H Keipp Talbot
Journal:  N Engl J Med       Date:  2014-08-14       Impact factor: 91.245

4.  Comparative effectiveness of high-dose versus standard-dose influenza vaccines in US residents aged 65 years and older from 2012 to 2013 using Medicare data: a retrospective cohort analysis.

Authors:  Hector S Izurieta; Nicole Thadani; David K Shay; Yun Lu; Aaron Maurer; Ivo M Foppa; Riley Franks; Douglas Pratt; Richard A Forshee; Thomas MaCurdy; Chris Worrall; Andrew E Howery; Jeffrey Kelman
Journal:  Lancet Infect Dis       Date:  2015-02-09       Impact factor: 25.071

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.